Strong quarterly updates, rising diagnostic demand, and improving investor confidence drive sharp gains in healthcare counters
Healthcare and diagnostic stocks emerged as major outperformers in an otherwise weak market on Friday, as investors rushed into quality healthcare names following strong business updates, healthy growth outlooks, and improving sector sentiment.
Shares of leading diagnostic companies including Metropolis Healthcare, Thyrocare Technologies, Dr Lal PathLabs, and Vijaya Diagnostic Centre rallied sharply during intraday trade despite weakness in broader benchmark indices.
The rally highlighted growing investor preference for defensive sectors such as healthcare amid volatile global market conditions and rising uncertainty surrounding inflation, oil prices, and geopolitical tensions.
Metropolis Healthcare Hits Fresh 52-Week High
Among the top gainers, Metropolis Healthcare surged as much as 14 per cent during intraday trade to touch a fresh 52-week high of ₹574.45.
The stock witnessed exceptionally strong trading volumes, with combined turnover across the NSE and BSE rising more than tenfold compared to average trading activity. Investors responded positively to the company’s strong Q4 business update and expectations of continued earnings momentum.
The company reported 23 per cent year-on-year revenue growth during the March quarter, driven by healthy traction in its wellness and specialised testing segments. Growth remained robust across both business-to-business and direct consumer channels.
Analysts believe Metropolis is benefiting from improving test volumes, stronger premium test mix, and expanding consumer reach through its “Metropolis 3.0” growth strategy.
Thyrocare Technologies Gains on Strong Operational Performance
Shares of Thyrocare Technologies also witnessed strong buying interest, rallying nearly 12 per cent during the session.
The company reported healthy quarterly numbers supported by operational efficiency improvements, network expansion, and rising diagnostic volumes. Consolidated revenue grew 20 per cent year-on-year during Q4FY26, while profit after tax jumped more than 120 per cent.
Thyrocare processed nearly 59 million tests during the quarter, reinforcing its leadership position in India’s diagnostic testing industry.
Market experts believe the company’s strong scalability, expanding digital reach, and focus on affordable diagnostics continue to support long-term growth potential.
Vijaya Diagnostic Centre and Dr Lal PathLabs Extend Rally
Broader strength within the diagnostics sector was also visible in other major healthcare counters.
Shares of Vijaya Diagnostic Centre climbed nearly 7 per cent after the company reported its highest-ever quarterly revenue performance. Strong growth in pathology and radiology services, along with expanding network presence, boosted investor sentiment.
Meanwhile, Dr Lal PathLabs advanced around 5 per cent as brokerages remained optimistic about the company’s long-term growth outlook and market leadership position.
Analysts expect Dr Lal PathLabs to maintain strong earnings momentum over the next few years driven by improving test volumes, better business mix, and synergies from acquisitions.
Healthcare Sector Benefits From Defensive Investor Rotation
The strong rally in healthcare stocks comes at a time when broader markets remain volatile due to global uncertainties, geopolitical tensions, and concerns over rising crude oil prices.
Market participants are increasingly rotating toward defensive sectors such as healthcare and pharmaceuticals, which are generally considered more resilient during periods of economic uncertainty.
Healthcare companies are also benefiting from structural growth trends including rising preventive healthcare awareness, increasing diagnostic penetration, digital healthcare adoption, and growing health insurance coverage across India.
Analysts See Long-Term Growth Potential in Diagnostics Industry
Brokerages and sector analysts remain optimistic about India’s organised diagnostics sector due to low penetration levels, increasing urban healthcare demand, and the shift toward branded healthcare providers.
Analysts believe organised diagnostic chains are likely to gain market share from smaller unorganised players as consumers increasingly prioritise quality, reliability, and technology-driven healthcare services.
Competition from low-cost online diagnostic startups has also moderated compared to the post-pandemic period, reducing pricing pressure for established players.
Strong Earnings Visibility Keeps Sector Attractive
The diagnostic sector continues to attract investor attention because of its relatively stable cash flows, scalable business models, and improving profitability metrics.
Experts believe companies with strong brand recognition, extensive testing networks, and direct-to-consumer capabilities are well-positioned to benefit from long-term healthcare demand growth in India.
With earnings momentum remaining strong and investor appetite for defensive growth sectors increasing, healthcare and diagnostics stocks may continue to remain in focus in the coming quarters.